Dr. Sarah M. Tolaney discusses breast practices associated with CDK4/6 inhibitors for the treatment of breast cancer.

AstraZeneca has reported positive outcomes from a planned interim analysis of the double-blind Phase III SERENA-6 trial of camizestrant plus a cyclin-dependent kinase (CDK) 4/6 inhibitor as first-line ...

Dr. Kevin Kalinsky discusses the role of targeted therapy and clinical decision-making in managing estrogen-driven, ...

New agents targeting endocrine therapy and CDK4/6 resistance in hormone receptor–positive breast cancer are in development.

The Phase III SERENA-6 trial is the first global trial to use a circulating tumor DNA-guided approach to detect endocrine ...

AstraZeneca could become the first company to bring an oral selective oestrogen receptor degrader (SERD) drug to market as a first-line treatment for breast cancer after camizestrant hit the mark in a ...

Topline results from the Phase III VERITAC-2 trial found that vepdegestrant provided a statistically significant and clinically meaningful improvement in progression-free survival in patients with ER+ ...

Get Instant Summarized Text (Gist) Cyclin-dependent kinase 2 (CDK2) is identified as a potential target for cancer therapy, particularly in overcoming resistance to CDK4/6 inhibitors used in ...

The early findings from the SERENA-6 trial indicate that the investigational oral SERD camizestrant provides a “highly statistically significant and clinically meaningful” improvement in ...